BACKGROUND AND OBJECTIVE The long term effects of fingolimod, an oral treatment for relapsing-remitting (RR) multiple sclerosis (MS), on blood circulating B and T cell subtypes in MS patients are not completely understood. This study describes for the first time the longitudinal effects of fingolimod treatment on B and T cell subtypes. Furthermore, expression of surface molecules involved in an...

Background Multiple sclerosis (MS) commonly includes anomia and other communicative deficits that affect participation quality of life. Anomia treatment in MS is currently unexplored. Owing to the degenerative nature MS, compensatory might be preferable restorative treatment. Semantic feature analysis (SFA) has been reported have a effect aphasia traumatic brain injury, it can also used as word...

I. Introduction: In Multiple Sclerosis (MS) neither the pathogenesis of the disease nor the mechanism of an action of immunomodulating therapies (IMT " S) are fully understood [1,2,3]. Genetic predispositions, socioeconomic influences, gender (females: males = 2:1), infectious agents, and other environmental factors have been implicated [4,5]. Identifying treatment has been challenging since th...

background while there is currently no cure for multiple sclerosis (ms), treatment with biologic diseasemodifying drugs (bdmds) can reduce the impact of the condition on the lives of patients. in greece, the regulatory change in the distribution system of bdmds, limited their administration through the designated pharmacies of the national organization for healthcare services provision (eopyy) ...

This PDF was generated from an article on http://drhoffman.com/ © 2017 Ronald L. Hoffman MD, PC. All Rights Reserved | 1 In a recent podcast, I made the case for natural treatment of multiple sclerosis with diet, supplements, and other innovative therapies. My experience while treating MS patients for over thirty years has convinced me that while drugs have limited benefits (and many carry with...

The unmet need for therapies capable of repairing the central nervous system (CNS) damage occurring in many diseases including multiple sclerosis (MS) has sparked the interest of the neurological community for stem cell-based therapies. An exhaustive amount of preclinical data has shown that the intravenous administration of mesenchymal stem cells (MSC), a subset of progenitor cells isolated fr...

BACKGROUND Due to a heightened risk of progressive multifocal leukoencephalopathy (PML) with increased natalizumab exposure, some physicians interrupt treatment of patients with multiple sclerosis (MS) despite a lack of data regarding the safety of treatment interruption, the rate and severity of MS disease activity return after treatment interruption, or alternative treatment strategies. OBJ...

Multiple Sclerosis is a chronic neurological disease that is accompanied by inflammation and myelin deficiency, and this pathological myelin disorder is irreversible. The prevalence of this disease is in 20-40 ages, and the rate of its prevalence in women is 1.7 times more than men. Yet, no effective medicine has been offered for this illness, and the present treatment methods are costly. Regar...